Checkmate Pharmaceuticals Inc. Common Stock
(NASDAQ:CMPI)
Description
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
CMPI Overview
None
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$14.6500 |
Previous Close Volume |
19975 |